[Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
It is shown that the heart rate (HR) is a predictor of the general and cardiovascular death rate. Ivabradine, being the If current inhibitor, induces a selective reduction in the HR and produces related positive effects on the course of basic cardiovascular diseases including ischemic heart disease, arterial hypertension, chronic heart failure, atherosclerosis, etc. Ivabradine is the powerful antiischemic and antianginal drug that acts by means of selective HR decrease. It can be used both in monotherapy and in a combination with beta-adrenoblockers. Ivabradine improves the function of left ventricule at chronic heart failure, increases stroke volume, and maintains cardiac output on a higher level. It optimises the energy consumption by myocardium and reduces heart electrophysiological and structural remodeling at patients with chronic heart failure and left ventricular systolic dysfunction. The drug also produces a pronounced antiatherogenic effect.